USANA Health Sciences (NYSE:USNA) Shares Down 2.1% on Insider Selling

USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report)'s stock price traded down 2.1% on Friday after an insider sold shares in the company. The stock traded as low as $29.79 and last traded at $29.73. 10,077 shares traded hands during trading, a decline of 90% from the average session volume of 100,948 shares. The stock had previously closed at $30.37.

Specifically, insider Joshua Foukas sold 5,732 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $32.54, for a total transaction of $186,519.28. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider David Mulham Mulham sold 3,234 shares of USANA Health Sciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $32.98, for a total value of $106,657.32. Following the completion of the transaction, the insider now directly owns 12,775 shares of the company's stock, valued at approximately $421,319.50. This represents a 20.20 % decrease in their position. The disclosure for this sale can be found here.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on USNA. DA Davidson cut their price objective on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, February 27th. StockNews.com lowered USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a report on Friday, February 14th. Finally, Sidoti lowered USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 18th.

Remove Ads

USANA Health Sciences Stock Down 0.9 %

The stock has a market capitalization of $524.12 million, a PE ratio of 9.80, a PEG ratio of 0.93 and a beta of 0.98. The firm has a 50 day moving average price of $32.39 and a 200-day moving average price of $35.78.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.15. The company had revenue of $213.61 million during the quarter, compared to analysts' expectations of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. Equities analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On USANA Health Sciences

Several institutional investors and hedge funds have recently modified their holdings of the company. Barclays PLC increased its holdings in USANA Health Sciences by 111.9% during the 3rd quarter. Barclays PLC now owns 27,737 shares of the company's stock worth $1,052,000 after purchasing an additional 14,647 shares during the period. Rhumbline Advisers boosted its position in shares of USANA Health Sciences by 39.8% during the 4th quarter. Rhumbline Advisers now owns 49,390 shares of the company's stock worth $1,773,000 after acquiring an additional 14,068 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of USANA Health Sciences by 2.8% during the 4th quarter. Principal Financial Group Inc. now owns 53,603 shares of the company's stock worth $1,924,000 after acquiring an additional 1,480 shares in the last quarter. Pzena Investment Management LLC boosted its position in shares of USANA Health Sciences by 3.6% during the 4th quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company's stock worth $39,015,000 after acquiring an additional 37,466 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of USANA Health Sciences by 4.5% in the 3rd quarter. Geode Capital Management LLC now owns 297,120 shares of the company's stock valued at $11,269,000 after purchasing an additional 12,898 shares during the period. Hedge funds and other institutional investors own 54.25% of the company's stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.